Leukotriene B4 as a mediator of early and late reactions to antigen in humans: The effect of systemic glucocorticoid treatment in vivo

Freeland, Howard S.; Pipkorn, Ulf; Schleimer, Robert P.; Bascom, Rebecca; Lichtenstein, Lawrence M.; Naclerio, Robert M.; Peters, Stephen P.

doi:10.1016/0091-6749(89)90076-6

Cited by 66 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nasal allergen challenge, which reproduces the symptoms of rhinitis, in inducing pruritus, sneezing, and nasal blockage, is associated with the local release of histamine, prostaglandin D,, leukotriene (LT) C,, LTB,, and tryptase, as identified by analysis of sequential nasal lavages (34,35). These findings are consistent with mast-cell degranulation.…”

Section: Discussionsupporting

confidence: 74%

Mediator release is altered in immunotherapy‐treated patients: a 4‐ear study

Dokic

Nethe

Kleine‐Tebbe

et al. 1996

Allergy

View full text Add to dashboard Cite

In recent years, it has been possible to demonstrate mediator release into the nasal secretion after nasal allergen challenge in patients with allergic rhinitis. Using the nasal provocation model, we determined whether the mediator release was altered in immunotherapy-treated patients. Seventeen grass-pollen-allergic patients were examined under controlled, reproducible conditions. Serial challenges with increasing doses of grass pollen produced increasing numbers of clinical symptoms and release of mediators such as kinins, TAME-esterase activity, and histamine. Ten patients received a semidepot perennial grass-pollen extract for 4 years. Seven patients served as controls and did not receive immunotherapy during the observation period. Data from the group of patients receiving immunotherapy over the first year already showed a partially significant decline in the maximal mediator release after nasal allergen challenges compared to the results of pretreated challenges, whereas controls did not show any significant changes. Nasal allergen challenges after termination of 4 years' immunotherapy significantly modified the mediator release compared to pretreatment values (TAME-esterase activity P < 0.05, kinins P < 0.01, and histamine P < 0.01).Decrease of mediator release paralleled the symptom-medication scores and quantitative skin prick test. Finally, we could demonstrate a significant correlation between specific IgG increase and mediator decrease in the treated group.Immunotherapy in patients with pollen allergy has been evaluated by the following criteria: 1) clinical parameters (symptom/medication scores) 2) rhinomanometry (difficult to assess because of 3) direct inquiry, which is highly subjective on the 4) the quantitative skin prick test (QST).Better reproducibility of results was achieved with immunoglobulin measurements (specific IgG and specific IgE), although a statistically significant relation has so far been detectable only between the applied cumulative dose during immunotherapy and the production of IgG antibodies. A direct correlation has not yet been clearly demonstrated between the clinical effectiveness of immunotherapy and IgG antibody production poor reproducibility) part of both the physician and the patient

show abstract

Section: Discussionsupporting

confidence: 74%

Mediator release is altered in immunotherapy‐treated patients: a 4‐ear study

Dokic

Nethe

Kleine‐Tebbe

et al. 1996

Allergy

View full text Add to dashboard Cite

show abstract

“…Correspondence to: C. Chavis inhibit neutrophil LTB 4 production [9,10]. Nevertheless, the effect of antiinflammatory drug treatments are usually associated with inhibition of neutrophil chemotactic activity [11,12] which was found to be related to a decreased capacity of PMNs to generate LTB4.…”

Section: Introductionmentioning

confidence: 99%

Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis

et al. 1995

View full text Add to dashboard Cite

The conversion of endogenous arachidonic acid (AA) by polymorphonuclear cells (PMN) from patients with rheumatoid arthritis (RA) was studied before (D0) and one day (D1) after antiinflammatory drug therapy. The biosynthesis of 5,15-diHETE and lipoxins (LXS), were investigated ex vivo, after PMN stimulation by ionophore A23187 without exogenous addition of 15-HETE. The eicosanoids were resolved by RP-HPLC and simultaneously detected at 246 and 302 nm respectively. Large amounts of 5,15-diHETE (50 to 400 ng/10(7) PMN) and significant levels of LXS (from 2 to 20 ng/10(7) PMN) were produced with individual differences between donors. Metabolite levels varied between patients but this work showed for the first time a linear relationship between the amounts of 5,15-diHETE and LXS. Moreover LXS production after treatment may be related to long-term clinical improvement of patients.

show abstract

“…Mast cell degranulation is evidenced by elevated tryptase, histamine, LTB 4 , LTC 4 and PGD 2 levels in the nasal lavage fluid of individuals with AR following nasal allergen provocation [73][74][75][76]. These mediators contribute to the sneezing, pruritus, rhinorrhea and nasal congestion characteristic of the early-phase symptoms of AR.…”

Section: Allergic Rhinitismentioning

confidence: 99%

The mast cell and allergic diseases: role in pathogenesis and implications for therapy

Brown

Wilson

Metcalfe

2007

Clin Experimental Allergy

243

184

View full text Add to dashboard Cite

SummaryMast cells have long been recognized for their role in the genesis of allergic inflammation; and more recently for their participation in innate and acquired immune responses. Mast cells reside within tissues including the skin and mucosal membranes, which interface with the external environment; as well as being found within vascularized tissues next to nerves, blood vessels and glandular structures. Mast cells have the capability of reacting both within minutes and over hours to specific stimuli, with local and systemic effects. Mast cells express the high affinity IgE receptor (FceRI) and upon aggregation of FceRI by allergen-specific IgE, mast cells release and generate biologically active preformed and newly synthesized mediators which are involved in many aspects of allergic inflammation. While mast cells have been well documented to be essential for acute allergic reactions, more recently the importance of mast cells in reacting through pattern recognition receptors in innate immune responses has become recognized. Moreover, as our molecular understanding of the mast cell has evolved, novel targets for modulation have been identified with promising therapeutic potential.

show abstract

Leukotriene B4 as a mediator of early and late reactions to antigen in humans: The effect of systemic glucocorticoid treatment in vivo

Cited by 66 publications

References 18 publications

Mediator release is altered in immunotherapy‐treated patients: a 4‐ear study

Mediator release is altered in immunotherapy‐treated patients: a 4‐ear study

Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis

The mast cell and allergic diseases: role in pathogenesis and implications for therapy

Contact Info

Product

Resources

About